Reaction Details Report a problem with these data
Target
Malignant T-cell-amplified sequence 1
Ligand
BDBM345320
Substrate
n/a
Meas. Tech.
Assay 4: MCT1-Mediated Lactate Transport in BT20 Breast Cancer Cells
IC50
45000±n/a nM
Citation
 Parnell, KM; McCall, J MCT4 inhibitors for treating disease US Patent  US10202350 Publication Date 2/12/2019 
Target
Name:
Malignant T-cell-amplified sequence 1
Synonyms:
MCT-1 | MCT1 | MCTS1 | MCTS1_HUMAN | Multiple copies T-cell malignancies
Type:
Enzyme Catalytic Domain
Mol. Mass.:
20563.62
Organism:
Homo sapiens (human)
Description:
n/a
Residue:
181
Sequence:
MFKKFDEKENVSNCIQLKTSVIKGIKNQLIEQFPGIEPWLNQIMPKKDPVKIVRCHEHIEILTVNGELLFFRQREGPFYPTLRLLHKYPFILPHQQVDKGAIKFVLSGANIMCPGLTSPGAKLYPAAVDTIVAIMAEGKQHALCVGVMKMSAEDIEKVNKGIGIENIHYLNDGLWHMKTYK
  
Inhibitor
Name:
BDBM345320
Synonyms:
2-([1-[(2-chlorophenyl)methyl]-5-(5-methoxythiophen-3-yl)-1H-pyrazol-3-yl]methoxy)-2-methylpropanoic Acid | US10202350, Example 66 | US10214492, Example 66 | US11292767, Example 66 | US11724989, Example 66
Type:
Small organic molecule
Emp. Form.:
C20H21ClN2O4S
Mol. Mass.:
420.91
SMILES:
COc1cc(cs1)-c1cc(COC(C)(C)C(O)=O)nn1Cc1ccccc1Cl
Structure:
Search PDB for entries with ligand similarity: